Clinical utility of a novel non-invasive technology for monitoring severe neutropenia in anticancer therapy.
Manuel Alva Bianchi(Research Institute Hospital 12 de Octubre), Branko Cuglievan(The University of Texas MD Anderson Cancer Center), Toshiaki Iwase(The University of Texas MD Anderson Cancer Center), Ana Jiménez Ubieto(Hospital Universitario 12 De Octubre), Ephraim P. Hochberg(Massachusetts General Hospital), Antonia Rodríguez Izquierdo(Hospital Universitario 12 De Octubre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), David McCall(The University of Texas MD Anderson Cancer Center), Anthony C Shelton, Alejandro Martínez‐Bueno(Hospital Universitario Dexeus), Eva Ciruelos(Hospital Universitario 12 De Octubre), Naoto T. Ueno(Breast Cancer Care), Tycho Baumann(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), José Manuel Pérez-García(MedSIR (Spain)), Juan Garcia(Instituto Oncológico Dr. Rosell), Pablo Justo Jiménez(Research Institute Hospital 12 de Octubre), César Núnêz(The University of Texas MD Anderson Cancer Center), Elizabeth Pottier, Andrea Martínez(The University of Texas MD Anderson Cancer Center), Pablo Tolosa(Research Institute Hospital 12 de Octubre)
Cited by 1
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927
Non-coding recurrent mutations in chronic lymphocytic leukaemia
|Nature|2015|851